FDA's Warning On Postmarketing Adverse Event Reporting To Actelion Signals Enforcement Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
While still much less frequent than GMP warning letters, PADE letters are on the rise, with FDA focusing on reports for drugs with known serious safety issues.
You may also be interested in...
Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture
FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.
Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture
FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.
FDA IND Safety Reporting Rule: New Types Of Data Must Be Submitted
Sponsors will have to provide new information to FDA under the agency’s final rule on investigational new drug safety reporting requirements.